Evidence map›Paper›PMID 31025289›Full record

ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2019

Cancer-Associated Fibroblasts Enhance Survival and Progression of the Aggressive Pancreatic Tumor Via FGF-2 and CXCL8.

Mohammad Awaji, Mitsuru Futakuchi, Tayla Heavican, Javeed Iqbal, Rakesh K Singh

Abstract read
In one paragraph

Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Overexpression ofSaudi journal of biological sciences · 2021
    Article
  18. Article
  19. Chemokine signaling in cancer-stroma communications.Journal of cell communication and signaling · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Mohammad AwajiDepartment of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Ctr., Omaha, NE, 68198-5900, United States.
Mitsuru FutakuchiDepartment of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Ctr., Omaha, NE, 68198-5900, United States.
Tayla HeavicanDepartment of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Ctr., Omaha, NE, 68198-5900, United States.
Javeed IqbalDepartment of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Ctr., Omaha, NE, 68198-5900, United States.
Rakesh K SinghDepartment of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Ctr., Omaha, NE, 68198-5900, United States. rsingh@unmc.edu.ORCID http://orcid.org/0000-0002-1317-3520
University of Nebraska Medical Center · USKing Fahad Specialist Hospital · SANagasaki University · JPNebraska Medical Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0M
Role of N-Cadherin in Pancreatic Tumor MicroenvironmentU54CA163120 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2011 to 2015
$4.2M
Targeting CXCR2 axis in Pancreatic CancerR01CA228524 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., SINGH, RAKESH K · 2018 to 2022
$2.0M
National Cancer Institute (US) R01CA228524, U54CA163120, P30CA036727NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA228524NCI NIH HHS U54 CA163120
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma remains one of the most challenging human cancers. Desmoplasia is predominant in this disease exhibiting a strong stromal reaction with an abundance of the cancer-associated fibroblasts (CAFs). We aimed in this study to investigate the reciprocal interaction between the tumor cells and the CAFs and its effect on tumor cells survival. We hypothesized that the survival of pancreatic cancer cell with aggressive phenotype is modulated by the Interactions between malignant pancreatic tumor cells and surrounding CAFs. To examine this, we utilized co-culture methods where tumor cells with different malignant potentials, HPAF (low) HPAF-CD11 (moderate/high) co-cultured with CAFs. CAFs-conditioned media increased the growth of HPAF-CD11 but not HPAF cells and increased CXCL8 levels highly in HPAF-CD11 and slightly in HPAF. The growth stimulatory effect and elevated CXCL8 level caused by CAFs-conditioned media were diminished by neutralizing the fibroblast growth factor-2 (FGF-2). In addition, conditioned media of HPAF-CD11 increased CAFs cell number whereas that of HPAF did not, and these effects were suppressed by neutralizing CXCL8. Furthermore, data from gene expression microarray study exhibited different expression profiles between HPAF and HPAF-CD11 when co-culture with CAFs. A significant increase in CXCL8 and FGF-2 expression was observed with HPAF-CD11/CAFs co-culture and to a lower extent with HPAF/CAFs co-culture. Together, these data demonstrate a paracrine bi-directional interaction between pancreatic tumor cells and the CAFs through CXCL8 and FGF-2 that helps the tumor growth. Future in-depth study of these pathways will assist in obtaining diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma.

Indexed as

Cell survivalCXCL8FGF-2Pancreatic tumorTumor progression

Identifiers

PMID31025289
PMCPMC6529493
OpenAlexW2941200763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.